新着情報

印刷

  • HOME
  • 新着情報
  • 【第27回先端研究セミナーのお知らせ「Evolution of cancer stem cells in glioma to promote their therapy resistant phenotype」Ichiro Nakano(Director of Neural Cancer Stem Cell Program, The Ohio State University)】

新着情報

【第27回先端研究セミナーのお知らせ「Evolution of cancer stem cells in glioma to promote their therapy resistant phenotype」Ichiro Nakano(Director of Neural Cancer Stem Cell Program, The Ohio State University)】

2014年08月11日

第27回先端研究セミナー

 

演題:Evolution of cancer stem cells in glioma to promote their therapy resistant phenotype

演者:Ichiro Nakano(Director of Neural Cancer Stem Cell Program, The Ohio State University)

 

抄録:High grade glioma (HGG) is a life-threatening brain tumor. Among heterogeneous tumor cells, glioma stem cells (GSCs) are defined as a subpopulation resistant to chemo- and radiotherapy with prominent tumorigenic ability. Identification of novel therapeutics designed to target the GSC population in HGGs is a challenge. The recent genome-wide transcriptome analysis identified 3 subtypes, proneural (PN), proliferative, and mesenchymal (MES), in HGGs. These HGG subtypes harbor distinct gene signatures and altered signaling pathways with some clinical relevance. During malignant transformation, HGGs appear to gain therapy resistance, at least in part, through their phenotypic drift into mesenchymal tumors. In addition, some of the current therapies, if not all, appear to induce mesenchymal transformation of HGGs resulting in more therapy-resistant tumors. Nonetheless, identification of subtype-specific GSCs remains elusive. 

 My lab recently identified clinical HGG sample-derived two mutually-exclusive GSCs: PN and MES GSCs with striking phenotypic differences with clinical relevance (Mao et al., PNAS 2013). Transcritpome microarray analysis, miRNA profiling, and subsequent functional analysis demonstrated that distinct signaling pathways regulate tumorigenesis and propagation of the individual GSC subtypes. For example, PN GSCs are dependent on the oncogenic transcription factor c-Myb (Miyazaki et al., Clinical Cancer Res. 2012) and MES GSCs are dependent on the oncogene/mitotic kinase MELK and Survivin (Guvenc et al., Clinical Cancer Res. 2012; Gu et al., Stem Cells 2013; Joshi et al., Stem Cells 2013). Intriguingly, upon radiation treatment, PN GSCs gain the phenotypes of MES GSCs (PN-to-MES transformation; PMT), which are much more aggressive and radioresistant than original PN GSCs. Of note, targeting the MES-specific pathways partially blocks PMT of GSCs. These results may partially explain the molecular mechanisms underlying mesenchymal transformation of HGGs to promote therapy resistance. Here I summarize our latest data to elucidate the molecular mechanisms that drive GSC evolution to promote their therapy resistant phenotype.

 

日時:2014年9月30日(火) 16:00〜17:00

 

場所:研究所1F セミナー室B

 

連絡先:清宮啓之 (内線5491)

 

*外部の研究者のご来聴を歓迎いたします。尚、本セミナーの内容は専門的であり、 医学・生物分野の研究に携わる方を対象としております。

このページのTOPへ